All articles by GlobalData Healthcare

  1. AstraZeneca and Merck look to cash in on Lynparza as new standard of care in ovarian cancer

    AstraZeneca and Merck & Co. have entered into a rewarding period in their partnership to develop and commercialise Lynparza (olaparib),…
    Read More…

    23 Aug
  2. Compliance found wanting for patients using topical treatments to manage alopecia areata

    Over time, compliance rates for patients using topical treatments for chronic autoimmune diseases such as alopecia areata (AA) have decreased….
    Read More…

    23 Aug
  3. Janssen and AbbVie’s Imbruvica earns approval in two new settings from the EC

    The EC has approved the use of Imbruvica in combination with obinutuzumab (Gazyva, Roche) in adult patients with previously untreated…
    Read More…

    22 Aug
  4. FDA calls surprise AdCom meeting on Vascepa: what does this mean for its upcoming label expansion?

    On August 8, Amarin announced that the US Food and Drug Administration (FDA) decided to convene an advisory committee meeting…
    Read More…

    22 Aug
  5. Partnerships are shaping late-stage pipeline for ovarian cancer drugs

    The transformation in ovarian cancer treatment that began with the recent approvals of several targeted therapies is expected to be…
    Read More…

    20 Aug
  6. As US court bans compounding of endo hormone, data shows injectables are the largest service at 503B outsourcing facilities

    In the US, compounding is a practice by which an authorised person combines, mixes, or alters ingredients of a drug…
    Read More…

    19 Aug
  7. Authorised generics: a poorly known pharma tactic to fend off competition

    A battle has been intensifying over the past decade between the generics drug industry and companies with branded drugs that…
    Read More…

    14 Aug
  8. Roche’s IMvigor 130 study reads a positive result for co-primary endpoint in bladder cancer

    On 5 August, Roche announced that Tecentriq (atezolizumab) plus platinum-based chemotherapy successfully met its co-primary endpoint in the Phase III…
    Read More…

    13 Aug
  9. River Blindness: can prophylactic vaccines eliminate a common cause?

    River blindness, also known as onchocerciasis, is an infection caused by a parasitic worm that lives in black flies endemic…
    Read More…

    12 Aug
  10. Indolent Non-Hodgkin’s Lymphoma: Roche Dominates Landscape

    Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are two sub types of non-Hodgkin’s lymphoma (NHL) that are collectively referred…
    Read More…

    12 Aug
Close
Close
Close

Go Top